Colorectal cancer KRAS — Patients

 

The therascreen KRAS test reliably detects mutations of the KRAS gene, which are found frequently in colorectal cancer.
Information for Patients
  • Main Image Navi
 

The therascreen KRAS test:

  • Is the only FDA-approved test for KRAS mutation detection
  • Has widespread insurance coverage
  • Helps your doctor determine if you can benefit from a treatment with ERBITUX

Ask your oncologist for the FDA-approved therascreen KRAS test.

Metastatic colorectal cancer
About the therascreen KRAS test
Understanding insurance coverage
Learn more about ERBITUX
Back to topMetastatic colorectal cancer

What is metastatic colorectal cancer?

  • Colorectal cancer is a cancer in the large parts of the large intestine, the colon, or rectum
  • When the disease spreads to other parts of the body, it is called metastatic colorectal cancer


Back to topAbout the therascreen KRAS test

The  KRAS testtherascreen reliably detects mutations, or changes, in the KRAS gene within your metastatic colorectal tumor. The status of the KRAS gene helps your oncologist determine the best method of treatment.

  • If your KRAS gene status is normal, those results indicate that you may benefit from the drug therapy ERBITUX
  • If your KRAS gene is not normal, your doctor will determine an appropriate alternative treatment

If you, or someone you know, have been diagnosed with metastatic colorectal cancer, ask your oncologist about the only FDA approved KRAS test for patients with metastatic colorectal cancer, the therascreen KRAS test.


Back to topUnderstanding insurance coverage

The therascreen KRAS test is:

  • The only FDA-approved test for KRAS mutation detection
  • Approved based on Phase III clinical trial data with ERBITUX of patients with KRAS wild-type tumor
  • A standardized assay for reproducible results
therascreen KRAS testing enjoys widespread coverage

Public and private payers endorse the value of KRAS testing with strong coverage policies for approved indications. Below is a sample of payers that have published positive coverage policies for KRAS testing.

Payers that have published positive coverage policies for KRAS testing
Sample listing
Aetna Blue Shield of CA
Anthem/Wellpoint Healthnet
BCBS AL Highmark BCBS
BCBS FL Humana
BCBS IL United Healthcare
BCBS MI Palmetto GBA (Medicare)
BCBS TX  

Public and private payers recognize the value of KRAS testing in determining the appropriateness of ERBITUX (cetuximab) for a specific patient. The following payers require that a KRAS test be performed prior to prescribing.

Payers that require a KRAS test prior to prescribing
Private payers Medicare payers
Aetna CGS
Anthem/Wellpoint CGS Medicare
BCBS AL FCSO Medicare
BCBS FL Palmetto
Cigna WPS Medicare
Empire BCBS  
Horizon BCBS  
Humana  

To confirm individual patient benefits please call QIAGEN Reimbursement Solutions at: 877-7-MYQIAGEN (877-769-7424).

Representatives are available from 8:00 a.m. through 8:00 p.m. Eastern Time, Monday through Friday.

Important: Coverage information provided by QIAGEN is gathered from third-party sources and is presented for informational purposes only. Coverage for KRAS testing varies by patient and is subject to contracting, deductibles, and payment caps. This information does not guarantee payment and QIAGEN makes no warranty regarding this information, its completeness, accuracy, or timeliness. Payer policies are complex and change frequently, and providers are responsible for all decisions relating to coding and reimbursement submissions. QIAGEN recommends that you consult your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage and reimbursement issues.



QIAGEN has a broad portfolio of companion diagnostic products in development.


Resources

You are not authorized to download the resource

External Links
4
Find out more about ERBITUX (cetuximab).
The nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.
Information about colon and rectal cancer (one of the National Institutes of Health).
Information about colorectal cancer from the National Institutes of Health.